The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of adding cetuximab (Cmab) or panitumumab (Pmab) to irinotecan (IRI)-based chemotherapy in salvage line against KRAS wild-type patients with metastatic colorectal cancer (mCRC): Analysis of HGCSG0901 and 1002.
Koshi Fujikawa
No relevant relationships to disclose
Satoshi Yuki
No relevant relationships to disclose
Takahide Sasaki
No relevant relationships to disclose
Yasuo Takahashi
No relevant relationships to disclose
Ichiro Iwanaga
No relevant relationships to disclose
Minoru Uebayashi
No relevant relationships to disclose
Soh Saitoh
No relevant relationships to disclose
Masahiko Koike
No relevant relationships to disclose
Michio Nakamura
No relevant relationships to disclose
Yasushi Sato
No relevant relationships to disclose
Mineo Kudo
No relevant relationships to disclose
Miki Tateyama
No relevant relationships to disclose
Yasuyuki Kawamoto
No relevant relationships to disclose
Hiroyuki Hisai
No relevant relationships to disclose
Mayuko Saito
No relevant relationships to disclose
Manabu Onodera
No relevant relationships to disclose
Tomofumi Takagi
No relevant relationships to disclose
Yuh Sakata
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Merck; Otsuka; Synergy International; Taiho Pharmaceutical; Yakult
Yoshito Komatsu
Research Funding - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Novartis; Pfizer; Taiho Pharmaceutical; Yakult